Stone Investment Group Limited » Performance Data » EuroPlus Dividend Growth Fund

Ideal for investors seeking total return tax efficient dividend income via European exposure, combining growth potential over the mid to long-term, dividend income, and lower risk than the MSCI Europe Index.

Daily Prices

Series Type Code Current NAVPS Prior NAVPS NAVPS Change Net Asset Value Last Updated
A Front SCL715 $ 13.2062 $ 13.2462 -0.30% $ 19,846,682 2017-08-17
*B DSC SCL716 $ 12.5722 $ 12.6106 -0.30% $ 287,117 2017-08-17
F Eligible SCL717 $ 14.5138 $ 14.5575 -0.30% $ 4,996,216 2017-08-17
T8A Front SCL7158 $ 6.1974 $ 6.2162 -0.30% $ 473,727 2017-08-17
L Low SCL719 $ 16.7703 $ 16.8214 -0.30% $ 8,152,813 2017-08-17
* Closed to new purchases.

Series Rolling Returns (%)

Series 1 Month 3 Month 6 Month Year To Date 1 Year 3 Year 5 Year 10 Year Since Inception
A (2.0) (4.1) 13.2 10.0 5.3 5.4 11.1 n/a 3.4
Benchmark (1.0) (2.3) 11.5 10.3 14.4 6.8 14.1 n/a 3.7
B (2.0) (4.2) 12.8 9.6 4.6 4.8 10.5 n/a 2.8
Benchmark (1.0) (2.3) 11.5 10.3 14.4 6.8 14.1 n/a 3.7
F (1.9) (3.7) 14.0 10.9 6.6 6.6 12.3 n/a 4.4
Benchmark (1.0) (2.3) 11.5 10.3 14.4 6.8 14.1 n/a 3.7
L (2.0) (4.2) 12.9 9.7 4.7 4.8 10.5 n/a 9.5
Benchmark (1.0) (2.3) 11.5 10.3 14.4 6.8 14.1 n/a 3.7
T8A (2.0) (4.1) 13.1 10.0 5.2 5.4 11.0 n/a 3.3
Benchmark (1.0) (2.3) 11.5 10.3 14.4 6.8 14.1 n/a 3.7

Calendar Returns

CALENDAR RETURN 20162015201420132012201120102009200820072006
A -10.4 17.7 3.3 27.2 15.6 (0.1) (6.6) 13.1 (27.0)
B -11.0 17.1 2.7 26.4 14.7 (0.2) (7.1) 12.6 (27.2)
C 2.8 26.4 14.7 (0.3) (7.1) 12.6 (27.2)
F -9.6 19.0 4.4 28.5 16.9 0.4 (5.6) 14.1 (26.5)
T8A -10.6 17.8 3.3 27.1 15.7 0.3 (6.7) 12.4 (27.0)
T8B 2.9 26.8 14.9 (0.2) (7.1) 12.6 (27.2)
T8C 14.7 (0.3) (7.1) 12.4 (27.2)
L -11.0 17.2 2.8 26.6 15.0 (0.2)
Benchmark -3.1 15.7 2.5 33.8 16.6 (9.1) (1.2) 16.7 (32.3)
Benchmark: MSCI Europe $C

Growth of $10,000 Since Inception

Portfolio Composition (%)

Top Holdings (%)

HOLDINGS
1 Novartis AG, Registered 4.7
2 Unilever NV 4.5
3 Sampo Group 4.2
4 Cerved Information Solutions SpA 4.2
5 Newbelco SA/NV 4.2
6 Reckitt Benckiser 4.1
7 Reed Elsevier plc 3.8
8 Henkel AG & Co. 3.7
9 Kinepolis Group NV 3.7
10 CTS Eventim AG 3.4
Total 40.5%

Fund Management Expense Ratio As of December 31, 2016

A B F L T8A
2.81 3.46 1.79 3.40 2.95